Dry mouth, medically known as xerostomia, is a common yet often overlooked condition that affects millions of people worldwide. It occurs when the salivary glands fail to produce enough saliva, leading to discomfort, difficulty swallowing, impaired speech, and an increased risk of tooth decay and oral infections. Growing awareness of oral health has accelerated demand for dry mouth relief solutions, salivary gland disorder treatment, and products within the artificial saliva market. These trends are significantly contributing to the expansion of the Xerostomia Therapeutics Market, where pharmaceutical companies and healthcare providers are developing innovative therapies to improve patients' quality of life. 

The global xerostomia therapeutics market was valued at USD 2.31 billion in 2025 and is projected to grow from USD 2.40 billion in 2026 to USD 3.32 billion by 2034, registering a CAGR of 4.1% during the forecast period (2026–2034).

Understanding Xerostomia and Its Causes

Saliva plays an essential role in maintaining oral health by lubricating the mouth, aiding digestion, preventing bacterial growth, and protecting teeth from decay. When saliva production decreases, patients experience persistent dryness that can interfere with everyday activities and overall well-being.

Common causes of xerostomia include:

• Side effects of prescription medications
• Radiation therapy for head and neck cancers
• Autoimmune disorders such as Sjögren's syndrome
• Diabetes and neurological disorders
• Aging-related salivary gland dysfunction
• Smoking and dehydration

Early diagnosis and appropriate treatment are essential to prevent complications such as oral infections, gum disease, and nutritional deficiencies.

Growing Demand for Dry Mouth Relief Solutions

The increasing incidence of chronic illnesses and medication-related dry mouth has fueled demand for effective dry mouth relief solutions. Patients today have access to a wide range of products designed to provide immediate symptom relief while improving oral comfort.

Popular relief options include:

• Oral moisturizing sprays
• Hydrating mouth rinses
• Saliva substitute gels
• Sugar-free lozenges
• Prescription salivary stimulants
• Oral moisturizing toothpaste

Many over-the-counter products provide temporary symptom relief, while prescription therapies are recommended for individuals with severe or chronic xerostomia. Continuous product innovation is enabling longer-lasting hydration and improved patient convenience.

Advances in Salivary Gland Disorder Treatment

Modern salivary gland disorder treatment extends beyond symptom management by addressing the underlying causes of reduced saliva production. Physicians increasingly adopt personalized treatment strategies based on disease severity, medical history, and the patient's overall health.

Current treatment approaches include:

• Prescription sialogogue medications that stimulate saliva production
• Artificial saliva formulations for lubrication
• Management of underlying autoimmune disorders
• Adjusting medications that contribute to dry mouth
• Nutritional counseling and hydration therapy
• Regular dental monitoring to prevent oral complications

Researchers are also investigating regenerative medicine and biologic therapies that may restore salivary gland function, offering promising long-term treatment options for patients with chronic gland dysfunction.

Artificial Saliva Market Driving Innovation

The artificial saliva market has become one of the fastest-growing segments within xerostomia therapeutics. Artificial saliva products closely mimic the lubricating properties of natural saliva, providing comfort to patients whose glands produce little or no saliva.

Modern artificial saliva products are available in various formulations, including:

• Oral sprays
• Mouth gels
• Mouth rinses
• Lozenges
• Lubricating oral solutions

Manufacturers continue investing in advanced formulations that provide prolonged moisture retention, improved taste, and enhanced oral protection. These innovations are particularly beneficial for elderly individuals, cancer patients receiving radiotherapy, and people living with autoimmune disorders.

Key Growth Drivers of the Xerostomia Therapeutics Market

Several factors continue to support the expansion of the Xerostomia Therapeutics Market:

Increasing aging population

Older adults are more likely to experience dry mouth due to age-related gland dysfunction and multiple medication use.

Rising prevalence of chronic diseases

Conditions such as diabetes, Parkinson's disease, Sjögren's syndrome, and cancer treatments significantly increase xerostomia cases.

Growing awareness of oral healthcare

Patients and healthcare professionals increasingly recognize the long-term complications associated with untreated dry mouth.

Product innovation

Manufacturers continue introducing improved saliva substitutes, prescription medications, and oral moisturizing products that enhance treatment effectiveness and patient adherence.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/xerostomia-therapeutics-market

List of Key Companies                                             

• Acacia Pharma

• Church & Dwight Co., Inc.

• Cogate-Palmolive Company

• Forward Science

• GaxoSmithKline plc

• Hikma Pharmaceuticas PLC

• Lupin Pharmaceuticas, Inc.

• Mission Pharmaca Company

• OraCoat

• Parnel Pharmaceuticals, Inc.

• Pendopharm

• Pfizer Inc.

• Recordati Industria Chimica e Farmaceutica S.p.A

• Sun Pharmaceutica Industries Ltd.

• Synedgen, Inc.

Emerging Market Trends

Several technological and clinical trends are shaping the future of xerostomia treatment:

• Development of long-lasting oral moisturizers
• Increased availability of over-the-counter therapies
• Expansion of online pharmacy distribution channels
• Growing research into regenerative salivary gland therapies
• Personalized treatment strategies based on disease severity
• Greater integration of oral healthcare with oncology and geriatric care

These innovations are expanding treatment accessibility while improving patient outcomes.

Regional Market Outlook

North America currently holds the largest share of the Xerostomia Therapeutics Market due to high awareness levels, advanced healthcare infrastructure, and increasing diagnosis of dry mouth-related conditions.

Europe continues to witness stable market growth supported by an aging population, favorable healthcare systems, and expanding use of prescription therapeutics.

Asia-Pacific is projected to experience the fastest growth during the forecast period, driven by rising healthcare investments, growing awareness of oral diseases, expanding pharmaceutical manufacturing, and improved access to healthcare services.

Future Outlook

The future of Xerostomia Therapeutics is centered on personalized care, regenerative medicine, and innovative oral hydration technologies. Pharmaceutical companies are investing in therapies that not only relieve symptoms but also improve salivary gland function over the long term. As awareness of oral health continues to grow globally, demand for advanced dry mouth treatments and artificial saliva products is expected to increase steadily.

More Trending Latest Reports By Polaris Market Research:

Dermatology Drugs Market

Medical Tubing Market

Diabetic Neuropathy Treatment Market

Animal Wound Care Market

India Diagnostic Services Market

Virtual Visits Market

Europe Pneumococcal Vaccine Market

U.S. Sterilization Monitoring Market